Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.07
+0.29005.02%
Post-market: 6.170.1000+1.65%19:30 EDT
Volume:5.74M
Turnover:34.88M
Market Cap:2.13B
PE:-13.84
High:6.16
Open:5.96
Low:5.92
Close:5.78
52wk High:9.75
52wk Low:2.99
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.89
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:8.40
PE(LYR):-10.12

Loading ...

Nuvation Bio Posts Corporate Deck Highlighting Ibtrozi ROS1+ NSCLC Launch, Safusidenib IDH1 Glioma Program

Reuters
·
Jul 20

Nuvation Bio announces data from the Phase 2 J201 study

TIPRANKS
·
Jul 20

Nuvation Bio Reports Updated Phase 2 Safusidenib Data, Expands Idh1-mutant Glioma Studies

Reuters
·
Jul 20

Nuvation Bio - Reports 52% Confirmed Objective Response Rate in Phase 2 Safusidenib Study

THOMSON REUTERS
·
Jul 20

Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)

TIPRANKS
·
Jul 13

Nuvation Bio is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise

Reuters
·
Jul 07

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

THOMSON REUTERS
·
Jul 07

Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032

Reuters
·
Jul 01

Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says

MT Newswires Live
·
Jul 01

Nuvation Bio's Taletrectinib Enters UK Regulatory Review

MT Newswires Live
·
Jun 29

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-positive Non-small Cell Lung Cancer Validated in the United Kingdom

THOMSON REUTERS
·
Jun 29

Nuvation Bio (NUVB) Completes $250 Million Note Offering, Is The Stock Fully Priced?

Simply Wall St.
·
Jun 28

Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks

MT Newswires Live
·
Jun 26

Nuvation Bio prices upsized offering of $250M of convertible senior notes

TIPRANKS
·
Jun 26

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 Million of Convertible Senior Notes

THOMSON REUTERS
·
Jun 26

Nuvation Bio Slides on Planned $200 Mln Convertible Offering

Reuters
·
Jun 25

Nuvation Bio falls -10.1%

TIPRANKS
·
Jun 25

Nuvation Bio Plans USD 200 Million Convertible Senior Notes Offering Due 2032

Reuters
·
Jun 25

Nuvation Bio - to Offer $200 Mln Convertible Senior Notes Due 2032

THOMSON REUTERS
·
Jun 25